Data on diabetic macular edema patients showed 49.1% of those on ranibizumab monotherapy attained at least a 5-point improvement in National Eye Institute Visual Functioning Questionnaire 25 composite scores after 12 months, compared with 42.7% of those on ranibizumab plus laser therapy and 30.6% of those on laser-only treatment. However, further analysis is required to determine whether the drug's benefits will be sustained during the three-year study period, researchers reported in JAMA Opthalmology.
Ranibizumab outperforms laser in improving diabetic macular edema
SmartBrief Job Listings for Health Care
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
Meridian Health Plan